Physician profile
Michael Allen Mitchell
NPI 1770561904
$7,267.00
in general payments reported to CMS, 2019-2025
36 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $797 · 2021: $1,088 · 2022: $1,151 · 2023: $1,171 · 2024: $1,100 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Education: $74.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.72 |
| Education | $74.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,703.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $965.49 | 2022-2025 | Korlym |
| Lilly USA, LLC | $920.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $576.07 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $420.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $321.66 | 2019-2024 | Verquvo, Steglujan, Steglatro |
| Astrazeneca Pharmaceuticals LP | $305.13 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $228.86 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $217.29 | 2021-2025 | |
| Amgen INC. | $208.83 | 2019-2023 | Repatha, Otezla |
| Tandem Diabetes Care, INC. | $137.26 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Idorsia Pharmaceuticals US INC | $101.00 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $98.70 | 2022-2025 | Xyosted |
| Medtronic, INC. | $86.18 | 2023-2025 | Minimed 780g |
| Dexcom, INC. | $85.14 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $84.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.32 | 2021-2023 | Jardiance |
| Companion Medical, INC. | $74.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.68 | 2023-2025 | |
| Esperion Therapeutics, INC. | $54.77 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.43 | 2019-2022 | |
| Abbott Laboratories | $51.25 | 2021-2023 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $49.80 | 2019-2020 | |
| Eisai INC. | $42.98 | 2020 | |
| Halozyme INC | $40.33 | 2023 | |
| Nevro Corp. | $40.08 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $38.39 | 2019 | |
| Pfizer INC. | $35.12 | 2019-2024 | |
| Glaxosmithkline, LLC. | $34.82 | 2020 | |
| Exact Sciences Corporation | $33.13 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $31.95 | 2020 | |
| Ceribell, INC. | $28.74 | 2025 | Pocket Eeg Device |
| Cequr Corporation | $17.78 | 2025 | Cequr Simplicity |
| Mylan Specialty L.P. | $14.76 | 2020 | |
| Amarin Pharma, INC. | $11.62 | 2019 | |
| Beta Bionics, INC. | $6.46 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.